99mTc-exametazime as a breast tumor-seeking agent: Comparison with 99mTc-sestamibi

Journal of Nuclear Medicine

Volumn 45, Issue 12, 2004, Pages 2040-2044

  Wilczek, Brigitte ^a   Svensson, Leif ^a   Danielsson, Rimma ^a   Celebiouglu, Fuat ^a   Larsson, Stig A ^a   Jacobsson, Hans ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

99mTc exametazime; 99mTc sestamibi; Breast cancer; Chemotherapy resistance; Mammoscintigraphy

Indexed keywords

HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; BREAST TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG UPTAKE; FALSE POSITIVE RESULT; FEMALE; HISTOPATHOLOGY; HUMAN; PRIORITY JOURNAL; SCINTIMAMMOGRAPHY; COMPARATIVE STUDY; PATHOLOGY; SCINTISCANNING;

BREAST NEOPLASMS; FEMALE; HUMANS; TECHNETIUM TC 99M EXAMETAZIME; TECHNETIUM TC 99M SESTAMIBI;

EID: 16644379780     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Bombardieri E, Crippa F, Maffioli L, Greco M. Nuclear medicine techniques for the study of breast cancer. Eur J Nucl Med. 1997;24:809-824.
2. 99mTc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis. Semin Nucl Med. 1999;29:16-40.
3. Goldenberg DM, Nabi HA. Breast cancer imaging with radiolabeled antibodies. Semin Nucl Med. 1999;29:41-48.
4. Aktolun C, Bayhan H, Kir M. Clinical experience with Tc-99m MIBI imaging in patients with malignant tumors: preliminary results and comparison with Tl-201. Clin Nucl Med. 1992;17:171-176.
5. Khalkhali I, Mena I, Jouanne E, et al. Prone scintimammography in patients with suspicion of carcinoma of the breast. J Am Coll Surg. 1994;178:491-497.
6. 99mTc-sestamibi. Acta Radiol. 1999;40:394-399.
7. Minn H, Ahonen A, Paul R. Radiation effects on uptake of 99Tcm-hexamethylpropylene amine oxime (HMPAO) in head and neck tumours. Br J Cancer. 1991;64:735-740.
8. Rowell NP, Flower MA, McCready VR, Cronin B, Horwich A. The effects of single dose oral hydralazine on blood flow through human lung tumours. Radiother Oncol. 1990;18:283-292.
9. Rowell NP, Flower MA, Cronon B, McCready VR. Quantitative single-photon emission tomography for tumour blood flow measurement in bronchial carcinoma. Eur J Nucl Med. 1993;20:591-599.
10. 99mTc-labelled hexamethyl propylene amineoxime. Br J Surg. 1990;77:454-457.
11. 99mTc-HMPAO in metastatic thyroid cancer: first results. Nuc Compact. 1998;19:234-237.
12. Tzukamoto E, Takumara A, Sakurai Y, Saito H, Tamaki N. Tc-99m HMPAO in renal cell carcinoma metastases. Clin Nucl Med. 1997;22:569-570.
13. Otsuka N, Fukunaga M, Morita K, et al. Accumulation of 99m-Tc-HMPAO in photon deficient areas in bone scan of bone metastases from hepatocellular carcinoma. Ann Nucl Med. 1992;6:215-220.
14. 99mTc-ECD in rodent and human breast tumor cell lines in vitro. Ann Nucl Med. 1997;11:95-99.
15. Shrout PE, Fleiss JL. Interclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420-428.
16. Neirinckx RD, Burke JF, Harrison RC, Forster AM, Andersen AR, Lassen NA. The retention mechanism of technetium-99m-HM-PAO: intracellular reaction with glutathione. J Cereb Blood Flow Metab. 1988;8(suppl 1):S4-S12.
17. Suess E, Malessa S, Ungersböck K, et al. Technetium-99m-d,l- hexamethylpropyleneamine oxime (HMPAO) uptake and glutathione contents in brain tumors. J Nucl Med. 1991;32:1675-1681.
18. Murray GI, Burke MD, Ewen SW. Glutathione localisation in benign and malignant human breast lesions. Br J Cancer. 1987;55:605-609.
19. 99mTc]-d,l-HM-PAO compared to xenon-133. J Cereb Blood Flow Metab. 1988;8(suppl 1):S69-S81.
20. 99mTc-HMPAO as a tumour blood flow agent. Eur J Nucl Med. 1987;13:90-94.
21. Rowell NP, McCready VR, Tait D, et al. Technetium-99m HMPAO and SPECT in the assessment of blood flow in human lung tumours. Br J Cancer. 1989;59:135-141.
22. m-HMPAO SPECT. Nucl Med Commun. 1989;10:325-334.
23. Ohnishi T, Noguchi S, Murakami N, et al. Early and delayed imaging of Tc-99m HMPAO versus Tl-201 in benign and malignant thyroid tumors: similar uptake but different retention. Clin Nucl Med. 1992;17:806-811.
24. 99mTc-HMPAO tumor scintigraphy using VX-2 tumors in rabbits. Kaku Igaku. 1991;28:1049-1056.
25. 99mTc-HMPAO in detection of breast cancer [abstract]. Eur J Nucl Med. 2002;29(suppl 1):S69.
26. 99mTc-HMPAO: kinetics of uptake and imaging of tumour [abstract]. Eur J Nucl Med. 2003; 30(suppl 2):S289.
27. 99mTc-MIBI in rabbits bearing VX-2 cancer. Kaku Igaku. 1995;32:199-203.
28. Chuman Y, Chen ZS, Sumizawa T, et al. Characterization of the ATP-dependent LTC4 transporter in cisplatin-resistant human KB cells. Biochem Biophys Res Commun. 1996;226:158-165.
29. Friedman HS, Colvin OM, Kaufmann SH, et al. Cyclophosphamide resistance in medulloblastoma. Cancer Res. 1992;52:5373-5378.
30. Keppler D, Leier I, Jedlitschky G, Konig J. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance protein MRP1 and its apical isoform MRP2. Chem Biol Interact. 1998;111-112:153-161.
31. Barnouin K, Leier I, Jedlitschky G, et al. Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione. Br J Cancer. 1998;77:201-209.
32. Broxterman HJ, Schuurhuis GJ. Transport proteins in drug resistance: detection and prognostic significance in acute myeloid leukemia. J Intern Med. 1997;740(suppl):S147-S151.
33. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol. 1997;40(suppl):S3-S8.
34. Vecchio SD, Ciarmiello A, Potena MI, et al. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med. 1997;24:150-159.
35. Kostakoǧlu L, Kiratli P, Ruacan S, et al. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med. 1999;39:228-234.